CRSP Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.
CRISPR Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$67.77|
|52 Week High||US$208.18|
|52 Week Low||US$64.76|
|1 Month Change||-18.08%|
|3 Month Change||-32.41%|
|1 Year Change||-66.10%|
|3 Year Change||82.52%|
|5 Year Change||265.53%|
|Change since IPO||380.98%|
Recent News & Updates
Crispr Therapeutics' Giant Leap For Humankind
Crispr Therapeutics uses a technology called Crispr-Cas9 to edit genes. Crispr-Cas9 allows gene editing to be cheap, fast, and accurate creating massive potentials for Crispr Therapeutics. Gene-based diseases like Sickle Cell Disease may finally be treatable. However, because the company is in the pre-revenue stage with questionable future scalability and margins, I think it is better for investors to stay on the sidelines and hope that this revolutionary technology helps the people in need.
Crispr Therapeutics: Buy The Dip On Promise Of Vertex Collaboration
CRISPR Therapeutics is a gene therapy company pioneering the CRISPR/Cas9 gene editing tool, discovered by its scientific co-founder. The company is partnered with Vertex - a $58bn market cap biotech with >$6bn in cash - on its lead program in Sickle Cell Disease. An approval could be in the offing - bluebird is its chief rival, but 2 gene therapy approvals may not damage the >$1bn peak sales potential. In-vivo gene therapies and allogeneic cell therapies are an important part of CRISPR's pipeline also, a few years further back in the development process but exciting nonetheless. It's hard to explain why CRISPR shares have lost ~65% of their value since January, but it offers an opportunity to build a position in a biotech with downside protection, a $2.5bn cash position, and some potentially transformative therapies.
Crispr Therapeutics: An Interesting Company That Has Reconnected With A Fair Valuation
One of the company's co-founders won a Nobel prize in chemistry for her work done on the CRISPR technology. The company has revolutionary technology but is in the early stages of development. The company is currently valuated at half of its high from less than six months ago.
CRISPR's Life-Saving Technology Has Massive Potential
CRISPR Therapeutics AG is a pre-revenue company specializing in CRISPR-Cas9. It allows accurate genetic replacement of the disease-associated DNA. CTX001 is the treatment candidate for Sickle Cell Disease and Beta-Thalassemia from the collaboration between CRSP and Vertex Pharmaceuticals Incorporated. CTX001 has shown sustained positive results in its phase 1/2 clinical trials. We discuss whether investors should add CRSP stock now.
|CRSP||US Biotechs||US Market|
Return vs Industry: CRSP underperformed the US Biotechs industry which returned -14.3% over the past year.
Return vs Market: CRSP underperformed the US Market which returned 13.7% over the past year.
|CRSP Average Weekly Movement||8.2%|
|Biotechs Industry Average Movement||10.0%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CRSP's weekly volatility (8%) has been stable over the past year.
About the Company
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
CRISPR Therapeutics Fundamentals Summary
|CRSP fundamental statistics|
Is CRSP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRSP income statement (TTM)|
|Cost of Revenue||US$386.53m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||5.38|
|Net Profit Margin||45.64%|
How did CRSP perform over the long term?See historical performance and comparison
Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CRSP ($67.77) is trading below our estimate of fair value ($128.77)
Significantly Below Fair Value: CRSP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CRSP is good value based on its PE Ratio (12.6x) compared to the US Biotechs industry average (24.4x).
PE vs Market: CRSP is good value based on its PE Ratio (12.6x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: CRSP is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: CRSP is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.2x).
How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRSP's forecast earnings growth (15.7% per year) is above the savings rate (2%).
Earnings vs Market: CRSP's earnings (15.7% per year) are forecast to grow faster than the US market (13% per year).
High Growth Earnings: CRSP's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRSP's revenue (21.4% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CRSP's revenue (21.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRSP is forecast to be unprofitable in 3 years.
How has CRISPR Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRSP has high quality earnings.
Growing Profit Margin: CRSP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by 16% per year.
Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: CRSP's Return on Equity (16.4%) is considered low.
How is CRISPR Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CRSP's short term assets ($2.5B) exceed its short term liabilities ($96.2M).
Long Term Liabilities: CRSP's short term assets ($2.5B) exceed its long term liabilities ($212.6M).
Debt to Equity History and Analysis
Debt Level: CRSP is debt free.
Reducing Debt: CRSP had no debt 5 years ago.
Debt Coverage: CRSP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRSP has no debt, therefore coverage of interest payments is not a concern.
What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRSP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sam Kulkarni (42 yo)
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Centessa Pharmaceuticals Lim...
CEO Compensation Analysis
Compensation vs Market: Sam's total compensation ($USD9.11M) is above average for companies of similar size in the US market ($USD6.40M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
Experienced Management: CRSP's management team is considered experienced (3.2 years average tenure).
Experienced Board: CRSP's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.3%.
CRISPR Therapeutics AG's employee growth, exchange listings and data sources
- Name: CRISPR Therapeutics AG
- Ticker: CRSP
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$5.186b
- Shares outstanding: 76.53m
- Website: https://www.crisprtx.com
Number of Employees
- CRISPR Therapeutics AG
- Baarerstrasse 14
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 23:19|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.